#AntiPD1
LightNews LightNews
oncodaily.bsky.social
AntiPD1 in combination with antilag3 and ctla4 in head and neck cancers - Patrick Hwu
@patrickhwumd.bsky.social

oncodaily.com/science/2564...

#Cancer #CancerResearch #HeadCancer #NeckCancer #Medicine #Health #Oncology #OncoDaily
Patrick Hwu: AntiPD1 in combination with antilag3 and ctla4 in head and neck cancers - OncoDaily
Patrick Hwu: AntiPD1 in combination with antilag3 and ctla4 in head and neck cancers / antilag3, AntiPD1, cancer, CD8 T cell, CTLA4, fight against cancer,
oncodaily.com
March 17, 2025 at 8:47 PM
ccii-kyoto.bsky.social
"Insights from a 30-year journey: function, regulation & therapeutic modulation of PD1"
Fm @natrevimmunol.bsky.social 2023: a history of the development of #antiPD1 #immunotherapy by Honjo, Chamoto et al.
#Immunology #Immunosky
www.nature.com/articles/s41...
Insights from a 30-year journey: function, regulation and therapeutic modulation of PD1 - Nature Reviews Immunology
In this Perspective, Honjo and co-workers describe the discovery of PD1 and its journey to become a major target for cancer immunotherapy. It discusses the complex regulatory systems that govern PD1 e...
www.nature.com
January 30, 2025 at 5:05 AM
shanmugarajan.bsky.social
🔗 Check out the OncoDaily feature here: lnkd.in/eb-VTa67

#Glioblastoma #GBM #BrainCancer #CancerImmunotherapy #Immunotherapy #TME #antiPD1 #PNAS #OncoDaily #ResearchHighlight
LinkedIn
This link will take you to a page that’s not on LinkedIn
lnkd.in
September 17, 2025 at 7:04 PM
sigtrans-sttt.bsky.social
Researchers identify #VCP as a key regulator of CD8+ T cell suppression in #HCC, showing that targeting VCP restores T cell #Antitumor function and synergizes with #AntiPD1 therapy to overcome #Immunosuppression in the #TME. #medsky

#OpenAccess in #STTT: doi.org/10.1038/s413...
October 26, 2025 at 4:30 AM
ccii-kyoto.bsky.social
"Insights from a 30-year journey: function, regulation & therapeutic modulation of PD1"
From 2023: a history of the development of #antiPD1 #immunotherapy by Honjo, Chamoto et al. @natrevimmunol.nature.com
#Immunology #Immunosky
www.nature.com/articles/s41...
Insights from a 30-year journey: function, regulation and therapeutic modulation of PD1 - Nature Reviews Immunology
In this Perspective, Honjo and co-workers describe the discovery of PD1 and its journey to become a major target for cancer immunotherapy. It discusses the complex regulatory systems that govern PD1 e...
www.nature.com
May 28, 2025 at 2:05 PM
embomolmed.org
Soluble #CD27 differentially predicts resistance to #antiPD1 alone but not with anti-CTLA-4 in #melanoma

By I. Sam, N. Benhamouda, L. Biard, L. Da Meda, K. Desseaux, C. Lebbe, E. Tartour & colleagues @cancerparisnord.bsky.social @hopitalpompidou.bsky.social

➡️ doi.org/10.1038/s443...
March 31, 2025 at 7:20 PM
alicefrolov.bsky.social
Sharing a new data visualization exploring the phenotypic reprogramming of exhausted CD8+ T cells following PD-1 axis blockade.

#TcellExhaustion #CheckpointBlockade #TumorImmunology #CD8Tcells #AntiPD1 #Tpex #ImmuneCheckpoint #CancerImmunotherapy
Sharing a new data visualization exploring the phenotypic reprogramming of exhausted CD8+ T cells following PD-1 axis blockade. Figure: "Reprogramming exhausted CD8+ T cells with anti-PD-1 therapy" Subtitle: "Marker-defined transitions from terminal exhaustion toward progenitor/effector states after checkpoint blockade" The visualization employs a faceted marginal-distribution slope arrow design, functioning as a state-transition flow map. Each facet corresponds to a defined exhaustion-associated marker axis (TCF1, TOX, TIM-3, PD-1, GZMB, and Ki-67), with paired marginal distributions rendered pre- and post-treatment. Slope arrows connect the density centroids across conditions, encoding both the directionality and relative magnitude of population-level marker shifts. This approach was chosen to make explicit the differential mobilization of progenitor-exhausted (Tpex) versus terminally exhausted (Tex_term) subsets rather than collapsing the transition into a single trajectory summary. The simulated data are calibrated to reproduce trends consistent with the current literature. Under anti-PD-1, the TCF1+ TOX-intermediate progenitor compartment shows expansion accompanied by upward slope vectors in Ki-67 and GZMB, consistent with proliferative burst and reacquisition of effector potential. Concurrently, the TIM-3-high, TCF1-negative terminally differentiated fraction contracts, and its centroid displays limited displacement along the TCF1 axis, reflecting the constrained plasticity of terminally exhausted cells. This asymmetry underscores that checkpoint blockade preferentially acts on the Tpex reservoir rather than fully reverting terminal exhaustion, a distinction with direct implications for durability of response.
September 12, 2026 at 5:18 PM
bibliotecahuvh.bsky.social
871P Randomized phase II trial of nivolumab plus paclitaxel in subjects with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) unable for cisplatin (CP)-based chemotherapy (CT): NIVOTAX TTCC study www.annalsofoncology.org/article/S092... #hvhebron #onco [Text complet]
871P Randomized phase II trial of nivolumab plus paclitaxel in subjects with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) unable for cisplatin (CP)-based chemotherapy (CT): N...
Up to 20% of patients (pts) with R/M HNSCC who may need CT + antiPD1 are ineligible for CP. NIVOTAX evaluated the efficacy and safety of nivolumab + paclitaxel (N) in pts with untreated R/M HNSCC inel...
www.annalsofoncology.org
January 30, 2026 at 1:26 PM
jovitamezquitapla.bsky.social
Un article de gran interés en descobrir una peça #metabòlica que impacte en la eficàcia de la #immunoteràpia i té sinergia amb la teràpia #antiPD1 en el tractament dels #tumors #sòlids.
If you're not redirected in a few seconds, click here
email.labxmediagroup.com
March 30, 2025 at 1:25 PM
bionewscentral.com
A new study suggests that the organization of #ImmuneCells within #melanoma #tumors may help identify which patients will benefit from combination #immunotherapy after standard #AntiPD1 treatment fails. 
#TumorMicroenvironment #ImmunotherapyResponse
Tumor cellular neighborhoods predict melanoma response to combination immunotherapy – BioNews Central
A new study suggests that the organization of immune cells within melanoma tumors may help identify which patients will benefit from combination immunotherapy after standard anti-PD-1 treatment fails. ...
sbee.link
April 22, 2026 at 9:38 PM